Telix Pharmaceuticals Stock Earnings Reports

Key points for investors: Telix reported strong FY25 commercial performance with group revenue of USD 804 million (56% YoY growth) driven by its Precision Medicine business (USD 622 million, +22% YoY). Adjusted EBITDA was USD 39.5 million and Precision Medicine EBITDA improved ~25% to USD 216 million. The company ended the year with cash of USD 142 million after investing approximately USD 0.5 billion (self-funded) into pipeline, commercial infrastructure and manufacturing. Management reiterated a capital allocation strategy focused on reinvesting operating cash into R&D and growth rather than near-term EPS optimization. For FY26 Telix guided revenue of USD 950–970 million and plans R&D spend of USD 200–240 million (greater focus on therapeutics). Key commercial updates: successful early launch of Gozellix, dual-PSMA product strategy (Illuccix and Gozellix) to address different customer needs, and international market access expansion (EU, Japan, China). Key development catalysts and timing: resubmissions planned for Pixclara and Zircaix in 2026, ProstACT GLOBAL Part 1 safety/dosimetry data to be disclosed concurrent with FDA submission, Part 2 randomized recruitment progressing ex-U.S. with an interim/futility analysis expected later in the year (management referenced Q4 timing). The therapeutics pipeline now includes three programs in pivotal studies (prostate, renal, glioblastoma), with the company targeting therapeutic commercial inflection points around 2028. Strategy highlights: vertical integration in manufacturing/supply chain to secure delivery and IP, internal innovation capability development, and building a specialist commercial organization as a competitive moat. Risks/uncertainties called out: regulation and FDA review timing (some CRLs experienced), reimbursement variability across geographies (EU timing vs. U.S.), competitive pressure in PSMA space, and variable margins in acquired manufacturing businesses (RLS reported lower margins on third-party products). Overall, the narrative to investors is strong near-term commercial momentum funding an aggressive, self‑funded build-out of a diversified radiopharma platform focused on scaling Precision Medicine now and transitioning to higher-value therapeutics later.